aMRC Centre for Virus Research, University of Glasgow, Glasgow bDepartment of Virology, Imperial College NHS Trust cDepartment of Medicine, Imperial College London, London, UK.
AIDS. 2013 Sep 24;27(15):2485-8. doi: 10.1097/QAD.0b013e328363b1f9.
NS3 protease inhibitors are set to improve sustained virological response rates in HIV-positive patients with hepatitis C. We measured the prevalence of natural resistance polymorphisms in 38 acutely infected treatment-naive patients using direct and deep sequencing. Twenty six percent of patients (10/38) had a majority variant resistance mutation (in order of frequency; Q80K - 16%, V36M - 5%, T54S - 3%, V55A - 3%, and D168A - 3%). Low-frequency mutations were detected in all samples. Further studies are required to determine threshold levels associated with treatment failure.
NS3 蛋白酶抑制剂有望提高丙型肝炎合并 HIV 阳性患者的持续病毒学应答率。我们使用直接测序和深度测序，检测了 38 例急性感染初治患者中天然耐药突变的流行情况。26%的患者（10/38）存在主要变异耐药突变（按频率顺序排列；Q80K-16%，V36M-5%，T54S-3%，V55A-3%，D168A-3%）。所有样本均检测到低频突变。需要进一步研究来确定与治疗失败相关的阈值水平。
